Mirabella Financial Services LLP Purchases New Position in Zoetis Inc. (NYSE:ZTS)

Mirabella Financial Services LLP acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 60,803 shares of the company's stock, valued at approximately $11,880,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Cetera Investment Advisers boosted its position in Zoetis by 275.2% during the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company's stock worth $16,259,000 after purchasing an additional 70,476 shares during the period. Simplify Asset Management Inc. acquired a new position in Zoetis in the 3rd quarter valued at $11,684,000. Soltis Investment Advisors LLC acquired a new stake in shares of Zoetis in the first quarter valued at about $688,000. Bank Pictet & Cie Asia Ltd. increased its stake in shares of Zoetis by 41.0% in the second quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company's stock worth $6,501,000 after purchasing an additional 10,900 shares during the period. Finally, Swedbank AB lifted its position in shares of Zoetis by 56.2% during the 2nd quarter. Swedbank AB now owns 1,946,277 shares of the company's stock worth $337,407,000 after purchasing an additional 700,398 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Price Performance

Shares of ZTS stock traded up $1.74 during trading hours on Monday, reaching $178.70. 4,558,329 shares of the company were exchanged, compared to its average volume of 2,551,175. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market cap of $80.62 billion, a price-to-earnings ratio of 33.49, a P/E/G ratio of 2.71 and a beta of 0.90. The stock's fifty day moving average is $185.62 and its two-hundred day moving average is $180.72. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business's quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $1.36 EPS. Sell-side analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. Zoetis's payout ratio is presently 32.52%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ZTS shares. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. Stifel Nicolaus boosted their price target on Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Finally, Argus raised shares of Zoetis to a "strong-buy" rating in a report on Friday, August 9th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis currently has an average rating of "Buy" and an average price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.